Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium.
coronavirus disease 2019
corticosteroids
high-flow nasal oxygen
intensive care
mechanical ventilation
remdesivir
Journal
Critical care explorations
ISSN: 2639-8028
Titre abrégé: Crit Care Explor
Pays: United States
ID NLM: 101746347
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
entrez:
3
6
2021
pubmed:
4
6
2021
medline:
4
6
2021
Statut:
epublish
Résumé
To compare patient management and outcome during the first and second waves of the coronavirus 2019 pandemic. Single-center prospective cohort study. Tertiary-care University Hospital. All adult patients admitted in either the first (from March 15 to May 15, 2020) or second (from October 1 to November 30, 2020) wave of coronavirus disease 2019. None. Primary outcome was 30-day mortality. During the second wave of the coronavirus disease 2019 pandemic, 33 patients (4.8%) were transferred due to overcrowding and excluded from analysis. There were 341 (first wave of the coronavirus disease 2019 pandemic) and 695 (second wave of the coronavirus disease 2019 pandemic) coronavirus disease 2019 patients admitted to the hospital, with median age first wave of the coronavirus disease 2019 pandemic as 68 (57-80) and second wave of the coronavirus disease 2019 pandemic as 71 (60-80) ( The main therapeutic changes between the first wave of the coronavirus disease 2019 pandemic and the second wave of the coronavirus disease 2019 pandemic were use of steroids, unrestrictive use of high-flow nasal oxygen for hypoxemic patients, and transfer of patients to other geographic areas in the case of ICU overcrowding. These changes were associated with a decrease in 30-day mortality, ICU admission, and organ support.
Identifiants
pubmed: 34079951
doi: 10.1097/CCE.0000000000000438
pmc: PMC8162523
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0438Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Déclaration de conflit d'intérêts
The authors have disclosed that they do not have any potential conflicts of interest.
Références
Crit Care Med. 2021 Feb 1;49(2):209-214
pubmed: 33105150
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA. 2016 Feb 23;315(8):788-800
pubmed: 26903337
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1115-1124
pubmed: 32822208
Lancet Respir Med. 2020 Dec;8(12):1201-1208
pubmed: 32861276
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Crit Care. 2021 Jan 4;25(1):3
pubmed: 33397421
Am J Respir Crit Care Med. 2020 May 15;201(10):P19-P20
pubmed: 32223716
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Crit Care Med. 2021 Feb 1;49(2):351-353
pubmed: 33186138
Intensive Care Med. 2020 Feb;46(2):315-328
pubmed: 32040667
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
JAMA. 2020 Apr 21;323(15):1499-1500
pubmed: 32159735
Crit Care Med. 2021 Mar 1;49(3):e219-e234
pubmed: 33555780
JAMA Netw Open. 2021 Jan 4;4(1):e2034266
pubmed: 33464319
N Engl J Med. 2020 Nov 19;383(21):2030-2040
pubmed: 33031652
J Crit Care. 2018 Feb;43:81-87
pubmed: 28854400
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Intensive Care Med. 2020 Dec;46(12):2248-2251
pubmed: 33170330